Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ)

Core Insights - Design Therapeutics (DSGN) saw a ~15% increase in stock price following an upgrade from RBC Capital Markets, which changed its rating from Sector Perform to Outperform, highlighting a catalyst-rich period ahead for the company [2] Company Summary - The upgrade by RBC Capital Markets indicates a positive outlook for Design Therapeutics, suggesting that the company is entering a phase with multiple potential growth drivers [2]